Shopping Cart 0
Cart Subtotal
USD 0

ZIOPHARM Oncology Inc (ZIOP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Ziopharm Oncology Inc (Ziopharm), formerly EasyWeb Inc, is a next-generation immune therapies provider. The company offers controlled IL-12 and t-cell therapy. Its next-generation immune therapie platform provides turning cold tumors hot by activating an immune response and non viral genetic modification of CART-T cells and TCRs. Ziopharm develops novel gene expression, control and cell technologies to provide cell-based therapies for the treatment of cancer and graft-versus-host-disease. The company provides cancer care services for solid tumors, brain cancer, pediatric cancer, and blood cancer. Its products and technologies are used in the treatment of hematologic malignancies, solid tumors and graft-versus-host-disease. Ziopharm is headquartered in Boston, Massachusetts, the US.

ZIOPHARM Oncology Inc (ZIOP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

ZIOPHARM, Intrexon Enter into Agreement with NCI 11

Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 12

Ziopharm Expands Co-Development Agreement with Intrexon 13

Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 14

Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 16

Licensing Agreements 17

Ziopharm Ocology Enters into Licensing Agreement with Precigen 17

Predictive Therapeutics Enters into Licensing Agreement with ZIOPHARM Oncology 18

Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 19

Equity Offering 21

ZIOPHARM Oncology Prices Private Placement of Shares for USD50 Million 21

Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 22

Ziopharm Oncology Completes Public Offering Of Shares For USD 50 Million 23

ZIOPHARM Oncology Completes Public Offering Of Common Stock For USD 50 Million 24

ZIOPHARM Oncology Inc-Key Competitors 26

ZIOPHARM Oncology Inc-Key Employees 27

ZIOPHARM Oncology Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Aug 08, 2018: Ziopharm Oncology reports second quarter 2018 financial results and provides corporate update 29

May 10, 2018: Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update 33

Mar 01, 2018: Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 35

Nov 06, 2017: ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities 37

Jul 31, 2017: ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities 40

May 01, 2017: Ziopharm Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities 43

Feb 16, 2017: ZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on Recent Activities 46

Corporate Communications 48

Sep 04, 2018: Ziopharm Oncology announces Scott Braunstein, M.D., operating partner at Aisling Capital, nominated to Board of Directors 48

Aug 07, 2018: Ziopharm Oncology announces changes to its board of directors 50

Sep 28, 2017: ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer 51

Product News 52

Oct 23, 2017: A Virus, a Gene and a Pill Used to Harness the Immune System to Fight Brain Tumor in Children 52

09/01/2017: ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit 53

Clinical Trials 54

Jun 18, 2018: Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy 54

May 02, 2017: ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia 55

Jan 31, 2017: ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing Point-of-Care Approach 56

Other Significant Developments 57

Feb 06, 2018: Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ZIOPHARM Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 9

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ZIOPHARM, Intrexon Enter into Agreement with NCI 11

Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 12

Ziopharm Expands Co-Development Agreement with Intrexon 13

Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 14

Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 16

Ziopharm Ocology Enters into Licensing Agreement with Precigen 17

Predictive Therapeutics Enters into Licensing Agreement with ZIOPHARM Oncology 18

Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 19

ZIOPHARM Oncology Prices Private Placement of Shares for USD50 Million 21

Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 22

Ziopharm Oncology Completes Public Offering Of Shares For USD 50 Million 23

ZIOPHARM Oncology Completes Public Offering Of Common Stock For USD 50 Million 24

ZIOPHARM Oncology Inc, Key Competitors 26

ZIOPHARM Oncology Inc, Key Employees 27

ZIOPHARM Oncology Inc, Subsidiaries 28

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

ZIOPHARM Oncology Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.